Condition
HIV Vaccine
Total Trials
4
Recruiting
0
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (3)
Trial Status
Active Not Recruiting1
Terminated1
Completed1
Unknown1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06700447Not ApplicableActive Not Recruiting
Protecting Against HIV Vaccine Misinformation With Adolescent Girls and Young Women in South Africa
NCT05604209Phase 1CompletedPrimary
Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3M4 in Persons With HIV-1 Suppressed on ART
NCT02771730Phase 1Terminated
Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults
NCT05786937Phase 1UnknownPrimary
Therapeutic Vaccine Based on aDC1 Dendritic Cells for the Control of Viremia After ATI in HIV Infected Individuals
Showing all 4 trials